Psychedelic Funding Update: Q1 2026
Psychedelic Funding Update: Q1 2026
We have updated our Psychedelic Company Financing Tracker to reflect activity in Q1 2026.
Quarterly Fundraising Activity in Psychedelics
Psychedelic financing activity in the first quarter of 2026 was down slightly from Q4 2025, with $348M raised across 11 events.
The bulk of those aggregate inflows accrued to Compass Pathways, which raised $150M on the back of its second positive Phase 3 readout in February. The public offering saw shares priced at $8.00 apiece, though the companyās stock trades at under $6.00 at the time of writing. Aside from that offering, toward the end of February, the company announced further proceeds of around $200M as just over 35 million outstanding warrants were exercised.
Itās a welcome injection of capital for the company, which is rounding out its Phase 3 psilocybin for treatment-resistant depression (TRD) program with the goal of submitting a new drug application to FDA in the ...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks